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Physical activity enhances muscle mitochondrial gene expression, while inactivity and mitochondrial dysfunction are both risk factors for
developing diabetes. Defective activation of the transcriptional coactivator PGC-1a may contribute to the gene expression pattern observed in
diabetic and insulin-resistant skeletal muscle.We proposed that greater insight into themitochondrial component of skeletal muscle ‘‘diabetes’’ would
be possible if the clinical transcriptome data were contrasted with local muscle inactivity-induced modulation of mitochondrial genes in otherwise
healthy subjects. We studied PPARGC1A (PGC-1a), PPARGC1B (PGC-1h), NRF1, and a variety of mitochondrial DNA (mtDNA) and nuclear-
encoded mitochondrial genes critical for oxidative phosphorylation in soleus muscle biopsies obtained from six healthy men and women before and
after 5 weeks of local muscle inactivity. Muscle inactivity resulted in a coordinated down-regulation of PGC-1a and genes involved with
mitochondrial metabolism, including muscle substrate delivery genes. Decreased expression of the mtDNA helicase Twinkle was related to the
decline inmitochondrial RNA polymerase (r = 0.83, p < 0.04), suggesting that mtDNA transcription and replication are coregulated in humanmuscle
tissue. In contrast to the situation in diabetes, PGC-1h expression was not significantly altered, while NRF1 expression was actually up-regulated
following muscle inactivity. We can conclude that reduced PGC-1a expression described in Type 2 diabetes may be partly explained by muscle
inactivity. Further, although diabetes patients are typically inactive, our analysis indicates that local muscle inactivity may not be expected to
contribute to the decreased NRF1 and PGC-1h expression noted in insulin-resistant and Type 2 diabetes patients, suggesting these changes may be
more disease specific.
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TFB1M; TFB2M; MTERFFrom epidemiological studies, physical inactivity has been
identified as being one of the most important risk factors for the
development of cardiovascular and metabolic disease in
humans [5,17,18,30]. There is now emerging evidence from
large-scale gene expression studies that specific mitochondrial
defects could represent an important factor for the development
of insulin resistance and Type 2 diabetes [13,14,16,20,21,30].
Defective activation of the nuclear hormone receptor coacti-
vator PPARGC1A (PGC-1a), a master regulator of mitochon-
drial gene expression, has been proposed to contribute directly0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: Jamie.Timmons@cgb.ki.se (J.A. Timmons).to the development of Type 2 diabetes mellitus and insulin
resistance [13,15,16,20]. Specifically, it has been shown that
PGC-1a, PPARGC1B (PGC-1h), and NRF1 expression and
the expression of PGC-1a-regulated oxidative phosphorylation
(oxphos) genes are down-regulated in the skeletal muscle of
diabetic and prediabetic insulin-resistant subjects [13,16,20]. It
has also been demonstrated that a prevalent polymorphism in
PGC-1a is more common in patients with Type 2 diabetes [3].
Molecular support for PGC-1a_s role in coordinating mito-
chondrial function has accumulated with a variety of mecha-
nistic studies [11,15,31] demonstrating a central role for this
coactivator in mammalian energy metabolism [24]. Indeed,
PGC-1a also appears to regulate mitochondrial gene ex-
pression in response to exercise [22,24,25], potentially6) 165 – 172
www.el
Fig. 1. The effects of 5 weeks of inactivity on themRNA levels of human skeletal
muscle substrate delivery genes. Total RNAwas prepared and analyzed for citrate
synthase (CS), pyruvate dehydrogenase subunit A1 (PDHA1), carnitine pal-
mitoyl transferase 1B (CPT1B), and glucose transporter 4 (Glut 4) mRNA
expression, together with 18S as an internal standard, using real-time PCR with
an ABI 7700 system. Target genes were normalized to 18S through subtraction
(DDCt methods). Data are presented as means T SEM, given as fold decrease
from baseline (n = 6). *p < 0.05.
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physical activity [29]. This substantial volume of evidence
has positioned PGC-1a as playing a central role in the
development of Type 2 diabetes [14] and led to the premature
conclusion that PGC-1a activation is a logical objective for a
diabetes drug development program [4,13,19].
It is very important to consider that patients with diabetes
are generally physically inactive and thus it is important to
establish how ‘‘diabetes’’ interacts with muscle inactivity, to
facilitate the overall interpretation of muscle gene expression
changes. To interpret the available clinical data, we decided to
establish the impact of local muscle inactivity on healthy
skeletal muscle gene expression and then contrast this with
changes observed in patients. Indeed, it was recently concluded
[14] that it was an important objective to determine if down-
regulation of PGC-1a signaling was a primary or secondary
event in the pathogenesis of Type 2 diabetes. Our primary
objective was to establish if the PGC-1a-related transcript
response in patients [13,16,20] could be partly explained by
muscle inactivity. In addition, by contrasting the two transcript
analysis strategies we should be able to identify more clearly
‘‘diabetes’’-specific alterations. We utilized a model of skeletal
muscle disuse [1,2,6] to impose 5 weeks of muscle inactivity
on only one leg of healthy volunteers. Muscle biopsies were
obtained before and after this intervention period, from the
soleus, and RNA was prepared to profile PGC-1a, PGC-1h,
mitochondrial substrate delivery genes, nuclear-and mitochon-
drial DNA (mtDNA)-encoded oxphos genes, and regulators of
mitochondrial transcription and replication. This represents the
first analysis of the impact of muscle inactivity on human
mitochondrial transcript abundance.
Results
Coordinated down-regulation of substrate delivery genes
Oxidative ATP regeneration is a sequential process requiring
substrate delivery to the cell (carbon units and oxygen),
including acetyl group delivery to the mitochondria and
subsequent reducing equivalent production. It was therefore
important to characterize key genes responsible for mitochon-
drial substrate delivery. We demonstrated a substantial reduc-
tion in genes responsible for muscle Kreb-cycle function (citrate
synthase (CS), p = 0.03), acetyl group production (pyruvate
decarboxylase (PDH1A), p = 0.008), lipid transport (carnitine
palmitoyltransferase Type 1 (CPT1B), p = 0.002) and glucose
uptake (GLUT4 (SLC2A4), p = 0.004) (Fig. 1). Interestingly,
these four substrate delivery genes were expressed in a
coordinated manner, irrespective of tissue status, indicating
close physiological regulation of both lipid-and carbohydrate-
related substrate delivery genes (Fig. 2).
Nuclear-encoded oxphos genes are down-regulated by
inactivity
The extent to which nuclear DNA-and mtDNA-encoded gene
expression is coregulated at the transcript level is still unclear inhuman cells. We demonstrated that the nuclear-encoded oxphos
genes cytochrome c oxidase subunit 4 (COX4I1 (COXIV); p =
0.007) and succinate dehydrogenase (SDHA; p = 0.003) were
down-regulated following 5 weeks of inactivity (Fig. 3), while
uncoupling protein 3 (UCP3) expression was not significant
altered ( p = 0.1). UCP3 expression was, overall, not tightly
coordinated with the other oxphos genes. There was greater
intersubject variation for the mtDNA-encoded transcript ex-
pression and as a consequence none of the individual mtDNA-
encoded transcripts demonstrated a statistically significant
reduction (cytochrome b of complex III (MT-CYB; p = 0.2),
NADH dehydrogenase subunit 4 (MT-ND4; p = 0.1), and
cytochrome c oxidase subunit I (MT-CO1, p = 0.07)) (Fig. 3,F =
4.49, p = 0.04). The expression of MT-CYB, MT-ND4, and MT-
CO1 was, as expected, highly linearly correlated (r > 0.9).
Down-regulation of mtDNA replication and transcriptional
regulatory genes by inactivity
The apparent coregulation between some nuclear-encoded
and some mtDNA-encoded genes suggests that mtDNA
transcription was partially reduced as clearly several nuclear-
encoded transcripts were (Figs. 1 and 3). To provide evidence of
a coordinated reduction in the transcript abundance of oxphos
genes, we profiled key regulators of mtDNA replication and
transcription (Figs. 4A and 4B). The mtDNA helicase PEO1
(known as ‘‘Twinkle’’) and the mitochondrial RNA polymerase
(POLRMT) were down-regulated following 5 weeks of inac-
tivity ( p < 0.05). Furthermore, the magnitude of the reduction in
Twinkle correlated with the magnitude of the reduction in
POLRMT (r = 0.83, p = 0.04). In contrast, mitochondrial trans-
cription factor A (TFAM), transcription factor B1 mitochondrial
(TFB1M), transcription factor B2 mitochondrial (TFB2M),
mitochondrial transcription termination factor (MTERF), DNA
polymerase g subunit (POLG), and mitochondrial single-
Fig. 2. The interrelationship between the mRNA levels of substrate delivery genes in human skeletal muscle. Total RNAwas prepared and analyzed for CS, PDHA1,
CPT1B, and Glut 4 mRNA expression as described for Fig. 1. The linear correlations were established by regression analysis of the C t value for the individual genes
normalized to 18S and plotted in the six possible combinations. The square symbols represent the values from post-muscle unloading, while the diamonds represent
the baseline values.
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weeks inactivity in human soleus muscle (Figs. 4A and 4B).
PGC-1a transcript expression is substantially down-regulated
by inactivity
To determine if changes in PGC-1a expression matched
those observed in Type 2 diabetes, we profiled PGC-1a mRNA
using primers that avoid any of the common polymorphisms or
known splice variants. In addition, PGC-1a is thought toregulate tissue levels of PGC-1h (also altered in diabetes
patients) and thus we examined the relationship between PGC-
1a and PGC-1h transcript abundance across 12 human skeletal
muscle samples. As demonstrated in Fig. 5A, PGC-1a was
significantly down-regulated following 5 weeks of muscle
inactivity ( p = 0.03), while PGC-1h expression was not
significantly altered. Furthermore, we found a surprising
increase in NRF1 expression ( p = 0.007), providing a clear
contrast to previous findings from patients with diabetes
(NRF2a and NRF2h expression was unchanged; data not
Fig. 3. The effects of 5 weeks of inactivity on the mRNA levels of human
skeletal muscle oxphos genes encoded (A) by nuclear DNA and on oxphos
genes encoded (B) by the mtDNA. Total RNA was prepared and analyzed for
nuclear cytochrome c oxidase subunit IV (COXIV), succinate dehydrogenase 2
(SDHA), uncoupling protein 3 (UCP3), cytochrome b (MT-CYB), NADH
dehydrogenase subunit 4 (MT-ND4), and cytochrome c oxidase subunit I (MT-
C01) mRNA expression together with 18S as an internal standard, using real-
time PCR with an ABI 7700 system. Target genes were normalized to 18S
through subtraction (DDCt methods). Data are presented as means T SEM,
given as fold decrease from baseline (n = 6). *p < 0.05.
Fig. 4. The effects of 5 weeks of inactivity on the mRNA levels of human
skeletal muscle mtDNA replication machinery. Total RNA was prepared and
analyzed for: (A) mitochondrial RNA polymerase (POLRMT), DNA polymer
ase g (POLG), Twinkle, the mtDNA helicase (C10ORF2), and the single
stranded DNA-binding protein (ssBP1) mRNA expression and (B) mitochon
drial transcription factor A (TFAM), mitochondrial transcription termination
factor (MTERF), transcription factor B1 mitochondrial (TFB1M), and
transcription factor B2 mitochondrial (TFB2M). 18S was used as an interna
standard. Target genes were normalized to 18S through subtraction (DDC
method). Data are presented as means T SEM, given as fold decrease from
baseline (n = 6). *p < 0.05, for Twinkle p = 0.067.
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abundance was coregulated across all human muscle samples
(Fig. 5B). For PGC-1a to be responsible for human skeletal
muscle mitochondrial gene expression it would be logical for
PGC-1a mRNA abundance to be related to the transcript
abundance of a number of oxphos-related genes in human
skeletal muscle. In the present analysis we were able to
demonstrate that PGC-1a transcript abundance was related to
nine nuclear-and mtDNA-encoded genes (Table 1), supporting
the idea that PGC-1a regulates oxphos gene expression in
human skeletal muscle.
Discussion
In the present study we demonstrate that a coordinated
down-regulation of oxphos genes, including regulators of
mitochondrial DNA transcription and replication, occurs in
human skeletal muscle following a 5-week period of muscle
inactivity. This response is generally consistent with thecoordinated down-regulation of mitochondrial genes previous-
ly reported in Type 2 diabetes patients [16,20]. Our data would
suggest that physical inactivity may contribute to the decreased
PGC-1a expression in patients with diabetes [13,16,20], while
reduced NRF1 and PGC-1h (which were up-regulated and
unchanged, respectively, in the present study) appear more
disease specific. Although inactivity in humans had previously
been associated with reduced mitochondrial enzyme capacity,
this is the first study to identify which components of the
mitochondrial biogenesis pathway are specifically regulated in
response to muscle inactivity in humans.
Two large transcriptome analysis studies [16,20] followed
on from epidemiological evidence that genetic variation in
PGC-1a is related to the development of Type 2 diabetes [3].
Utilizing qPCR and microarrays the investigators proposed
that skeletal muscle insulin resistance involved a coordinated
down-regulation of oxphos genes as a consequence of
disrupted PGC-1a and NRF1 signaling [16,20] and potentially
of reduced PGC-1h [13]. Numerous in vitro and transgenic
studies from the same laboratories have strongly reinforced





Fig. 5. (A) The effects of 5 weeks of inactivity on the mRNA levels of
peroxisome proliferator-activated receptor-g coactivator-1a (PCG-1a) and
PGC-1h in human skeletal muscle. Total RNA was prepared and analyzed
for PGC-1a and PGC-1h mRNA expression together with 18S as an internal
standard, using real-time PCR with an ABI 7700 system. Target genes were
normalized to 18S through subtraction (DDC t methods). Data are presented as
means T SEM, given as fold change from baseline (n = 6). *p < 0.05. (B) The
interrelationship between the mRNA levels of PGC-1a and PGC-1h. Total
RNA was prepared and analyzed for PGC-1a and for PGC-1h mRNA
expression as described for panel A. The linear correlations were established by
regression analysis of the Ct value for the individual gene normalized to 18S
and plotted. The square symbols represent the values from post-muscle
unloading, while the diamonds represent the baseline values.
Table 1
Linear relationship between PGC-1a and oxphos gene expression
Gene Correlation coefficient
CS 0.59 p = 0.043
PDHA1 0.65 p = 0.023
CPT1B 0.73 p = 0.007
GLUT4 0.66 p = 0.019
MT-CYB 0.72 p = 0.009
MT-ND4 0.67 p = 0.017
MT-C01 0.69 p = 0.014
COXIV 0.72 p = 0.009
SDHA 0.41 p = 0.182
UCP3 0.76 p = 0.004
Skeletal muscle expression of the gene transcripts citrate synthase (CS),
pyruvate decarboxylase (PDH1A), carnitine palmitoyltransferase Type 1
(CPT1B), glucose transporter 4 (GLUT4), cytochrome b of complex III
(MT-CYB), NADH dehydrogenase subunit 4 (MT-ND4), cytochrome c oxidase
subunit I (MT-C01), cytochrome c oxidase subunit 4 (COXIV), succinate
dehydrogenase (SDHA), and uncoupling protein 3 (UCP3) were measured and
values were corrected to 18S. Relationships were profiled using linear
regression (n = 12).
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represents a therapeutic target for drug development [4,15].
Importantly, the metabolic consequences of PGC-1a and PGC-
1h expression are distinct, with PGC-1a promoting a more
uncoupled phenotype, while PGC-1h appears to promote gene
expression that favors coupling of oxphos in muscle cells [26]
such that selective modulators are presumably required.
In the present study we produced the first comprehensive
analysis of key regulators of mitochondrial biogenesis in
human skeletal muscle in response to muscle activation levels.
In general we provide evidence that in humans PGC-1a is
related to the expression of many oxphos and mitochondrial
substrate delivery genes (Table 1). This supports the idea that
PGC-1a expression is a key physiological regulator of tissue
oxidative capacity in human skeletal muscle (or that a common
factor regulates all the aforementioned genes). While PGC-1a
and PGC-1h mRNA content was regulated in a consistent
manner across all the muscle samples, PGC-1h was not down-
regulated by inactivity alone. This implies that the reduction in
PGC-1a expression in diabetes patients may partly reflect lackof physical activity as these patients are historically known to
be inactive. In contrast it is clear that muscle inactivity per se
has distinct effects on NRF1 and PGC-1h expression and that
lack of physical activity is not a compelling explanation for the
diabetes-related changes observed for NRF1 and PGC-1h.
Loss of PGC-1h expression in diabetes patients may, based on
muscle cell studies, promote energy conservation potentially
contributing to obesity [26].
The genuine molecular nature of the proposed mitochondrial
defect in insulin resistance and diabetes has eluded clear
identification in humans. What is clear is that the nature of the
‘‘mitochondrial defect’’ differs across different organs. For
example, it transpires that increased PGC-1a activity may
contribute to the failure of insulin to suppress postprandial
hepatic glucose output [11], while PGC-1a expression also
appears to be elevated, not suppressed, in glucose-insensitive
pancreatic h cells—actively contributing to impaired insulin
secretion [31]. It has recently been demonstrated that in two
separate European populations, no relationship between PGC-
1a Gly482Ser polymorphism and diabetes exists [27], which
makes some sense if the PGC-1a role varies, in opposite
directions, in the various insulin-sensitive organs. If PGC-1a
changes in skeletal muscle are secondary to inactivity then
perhaps altered expression of NRF1 and/or PGC-1h contributes
to the abnormal muscle mitochondrial metabolism and lipid
storage observed in diabetes. Furthermore, it is not unusual to
observe an increase in mitochondrial gene transcripts when a
primary mitochondrial defect exists within the mitochondrial
respiratory chain [8] as the cell attempts to compensate for the
‘‘primary’’ defect. Indeed, we believe that it is unlikely that a
single mitochondrial-related defect underlies the mitochondrial
phenotype observed in diabetes patients. This would also lead
one to conclude that the most effective method for selectively
stimulating mitochondrial growth in skeletal muscle may be a
program of physical therapy, which, depending on the intensity,
frequency, and timing of the posttraining glucose tolerance test,
reduces skeletal muscle insulin resistance in humans [10,23]. In
J.A. Timmons et al. / Genomics 87 (2006) 165–172170contrast, developing a muscle-specific ‘‘activator’’ of the PGC-
1a pathway may be extremely challenging, as PGC-1a does not
belong to a protein class that is easily amenable to pharmaceu-
tical manipulation by a drug-like molecule [9], and ultimately
exercise therapy is probably a simpler option, with greater
overall benefits.
In conclusion, we provide the first evidence that in humans,
inactivity results in a coordinated down-regulation of PGC-1a-
related oxphos genes and components of the mitochondrial
replication system at the transcript level. We also demonstrate a
surprising increase in NRF1 following muscle inactivity,
contrasting with the decreased NRF1 observed in diabetes
patients, and relatively unchanged expression of PGC-1h
(again contrasted with a decline in diabetes patients). This
suggests that reduced PGC-1a expression in the skeletal
muscle of Type 2 diabetes could be secondary to inactivity.
Clearly our initial study is limited by both sample size and the
lack of characterization of local muscle insulin sensitivity
(whole body glucose tolerance should have remained un-
changed). Future studies should focus on examining muscle
inactivity-induced changes in the mitochondrial proteome and
contrast this with observations made from insulin-resistant and
diabetic patients linking changes to directly assessed muscle
insulin sensitivity. When doing so it is probably important to
keep in mind that ‘‘insulin resistance’’ is more than impaired
glucose uptake and several biochemical markers of insulin_s
action should be measured. Finally, we would argue that
quantitative assessment of patient characteristics is essential for
future transcriptome characterization of muscle phenotype in
diabetes patients, especially as ‘‘new’’ targets are introduced as
having therapeutic merit. Indeed, when considering environ-
mental and genetic contributions to metabolic disease [13] it is
definitely worth considering that the tendency to participate in
physical activity may well be a component of both the
environmental and the familial influences on mitochondrial
gene expression in human skeletal muscle.
Research design and methods
Inactivity protocol and subject characteristics
Six healthy adult subjects, four men and two women,
volunteered for this study. At the time of being recruited the
subjects did not participate in any regular training programs. A
written consent was given after the procedures and risks
associated with participation in the study had been explained.
The experimental protocol was approved by the Institutional
Review Board at the University of Arkansas for Medical
Sciences (Little Rock, AR, USA) and the study was conducted
in accordance with the Declaration of Helsinki as revised in
2000. The subjects were between 30 and 56 years of age, with
a body fat range of 9–25% (calculated from biceps, triceps,
suprailiac, and front thigh skinfolds, using a Harpenden
caliper). The subjects had a body mass range of 57–91 kg
and a height range of 165–185 cm. The body mass and
calculated percentage body fat did not change during the study
period. Volunteers were subjected to unilateral unloading of thelower limb for 5 weeks as previously described [1,2,6],
refraining from any physical activity. The local muscle
inactivity resulted in an ¨12% reduction in muscle cross-
sectional area over the 5-week period. The physiological results
and global changes in muscle volume from this study have
been reported elsewhere [28]. Subjects lived at home and
carried out their normal work tasks throughout the experimen-
tal period. To ensure compliance all subjects were interviewed
by one of the investigators on a daily basis. Skin temperature
and circumference were measured midcalf at least twice
weekly during scheduled visits to the laboratory. The unloaded
calf consistently demonstrated a 2-to 3-cm greater circumfer-
ence than the weight-bearing limb, while calf temperature was
¨2–3-C lower ( p < 0.05) in the unloaded leg compared with
the weight-bearing leg during the study, indicating good
compliance [28]. As prophylaxis to venous thromboembolism,
subjects received a daily dose of 325 mg aspirin. In addition,
they wore knee-length, medical-graded (Class 2) compression
stockings (BSN-Jobst, Inc., Rutherford College, NC, USA)
during any ambulatory activity.
Quantitative real-time RT-PCR
Total RNA was isolated by the use of TRIzol (Invitrogen);
however, the RNA remained contaminated with DNA and this
created a problem when measuring mitochondrial mRNA
transcripts. To resolve this we treated each RNA sample with a
DNase treatment using the RNeasy Mini Kit column procedure
(Qiagen), followed by quantification using a spectrophotometer.
Two micrograms of RNA was reverse transcribed by reverse
transcription reagents (Applied Biosystems) using random
hexamer primers, in a total volume of 60 Al. Amplification
aliquots contained 5 Al of the sample cDNA, 2 TaqMan
Universal PCR Master Mix, and an optimized concentration of
each primer, added to a final volume of 25 Al, and were measured
in triplicate. The mix for 18S rRNAwas prepared according to
the manufacturer_s recommendation (Applied Biosystems) and
run in triplicate at 1:1000 dilution. Thermal cycling conditions
included 2 min at 50-C, 10 min at 95-C, and then 45 cycles each
of 15 s at 95-C and 1 min at 65-C. Oligonucleotide primers were
designed using a primer design center (http://www.probelibrary.
com/) and synthesized by Invitrogen (Stockholm, Sweden). The
primer sequences will be provided on request. The primers were
designed to amplify across exon–exon boundaries to avoid
amplification of genomic DNA. This was not possible for
mtDNA-encoded genes or CS as they are intronless. The 18S
rRNA was selected as an endogenous control to correct for
potential variations in RNA loading since there are no
established low-abundance housekeeping genes for this exper-
imental paradigm. The DDCt method [30] was used to calculate
relative changes in mRNA abundance. The threshold cycle (Ct)
for 18S was subtracted from the Ct for the target gene—to adjust
for variations in mRNA/cDNA generation efficacy. The
preintervention values reflect baseline gene expression levels
and were subtracted from the postexercise value to calculate the
increase or decrease in mRNA abundance. The changes are
described using the ‘‘fold changes’’ convention, in which a
J.A. Timmons et al. / Genomics 87 (2006) 165–172 171twofold increase is a doubling and a twofold decrease is a
reduction by half. All data are means T SEM. Following
ANOVA for global changes in gene expression, individual gene
expression data were compared using a paired-test, with precise
p values being presented. For the purpose of discussion a p <
0.05 was considered significant. Linear regression was utilized
to determine coexpression relationships across genes.
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